ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2019
Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Bladder Paraganglioma With Rapid Metastasis: A Case Report and Review of the Literature.Cureus · 2026Article
- Drive Time to Physicians and Outcomes for Bladder Cancer.JU open plus · 2025Article
- Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.BJU international · 2024Article
- Income Disparities in Survival and Receipt of Neoadjuvant Chemotherapy and Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer.Current oncology (Toronto, Ont.) · 2024Article
- Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older.Frontiers in oncology · 2024Article
- Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program.Journal of the National Cancer Institute. Monographs · 2023Article
- Article
- Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database.Cancer causes & control : CCC · 2023Article
- Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.BJU international · 2022Article
- Sociodemographic factors associated with Wilms tumor treatment and survival: a population-based study.International urology and nephrology · 2022Article
- Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer.Urologic oncology · 2022Article
- Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer.Journal of the National Cancer Institute · 2022Article
- Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer.Urology practice · 2021Article
- Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer.Cancer medicine · 2020Article
- A mediation analysis to explain socio-economic differences in bladder cancer survival.Cancer medicine · 2020Article
- Disparities in Bladder Cancer Outcomes Based on Key Sociodemographic Characteristics.Current urology reports · 2020Review
- Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation.Advances in radiation oncologyArticle
- Cancer treatment and survivorship statistics, 2025.CA: a cancer journal for cliniciansArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundRacial disparities in guideline-based, appropriate treatment (ApT) may be a significant driving force for differences in survival for people with nonmetastatic muscle-invasive bladder cancer (MIBC). We hypothesize that receipt of ApT is influenced by factors such as race and socioeconomic status, irrespective of neighborhood-level differences in healthcare, variations in practice patterns, and clinical characteristics of patients with nonmetastatic MIBC.
methodsWithin the National Cancer Database, we identified individuals diagnosed with MIBC between 2004 and 2013. Multivariable logistic regression and mixed effects modelling was used to examine predictors of ApT, clustered within institutions.
resultsA total of 51,350 individuals had clinically staged nonmetastatic, lymph node-negative MIBC. Black individuals comprised 6.4% of the cohort. Mean age was 72.6 years (SD 11.6) with a male predominance (71.4%). Less than half received ApT (42.6%). Fewer black individuals received ApT compared with white individuals (37% vs. 43%,
conclusionsRacial disparities in treatment persisted after accounting for various clinical factors and social determinants of health. Future efforts should focus on addressing racial bias to improve disparities in bladder cancer treatment. IMPACT: If we are not delivering evidence-based care due to these biases (after accounting for access and biology), then it is expected that patients will experience inferior outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.